Drug profile · INN
tenapanor hydrochloride
PHOZEVEL
tenapanor hydrochloride (PHOZEVEL) is a sodium/hydrogen exchanger 3 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — tenapanor hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
tenapanor hydrochloride (PHOZEVEL) is a sodium/hydrogen exchanger 3 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium/hydrogen exchanger 3 inhibitor
Primary target: Sodium/hydrogen exchanger 3
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Frequently asked questions
What is tenapanor hydrochloride?
tenapanor hydrochloride (PHOZEVEL) is a sodium/hydrogen exchanger 3 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for tenapanor hydrochloride?
PHOZEVEL is a marketed brand name for tenapanor hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tenapanor hydrochloride?
tenapanor hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.